60 Degrees Pharmaceuticals (SXTP) Other Non-Current Liabilities (2022 - 2024)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Other Non-Current Liabilities of $565949.0 for Q1 2024, down 62.25% year-over-year from $1.5 million in Q2 2023, and up 654.6% quarter-over-quarter from $75000.0 in Q4 2023.
60 Degrees Pharmaceuticals (SXTP) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Other Non-Current Liabilities for 3 consecutive years, with $565949.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Other Non-Current Liabilities fell 62.25% year-over-year to $565949.0; the TTM figure through Mar 2024 stood at $565949.0 (down 62.25% YoY), while the FY2023 annual figure was $75000.0, down 94.98% from the prior year.
- Other Non-Current Liabilities grew to $565949.0 in Q1 2024 per SXTP's latest filing, from $75000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.5 million in Q1 2023 and bottomed at $75000.0 in Q4 2023.
- Historically, Other Non-Current Liabilities has averaged $908620.8 across 3 years, with a median of $1.0 million in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities sank 94.98% — and 2024, when it sank 62.25%.
- 60 Degrees Pharmaceuticals' Other Non-Current Liabilities stood at $1.5 million in 2022, then plunged by 94.98% to $75000.0 in 2023, then surged by 654.6% to $565949.0 in 2024.
- Business Quant data shows SXTP's Other Non-Current Liabilities at $565949.0 in Q1 2024, $75000.0 in Q4 2023, and $1.5 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 565,949.00 |
| Dec 31, 2023 | 75,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.49 Mn |